Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Gynecologic Cancers | Faculty Presentation 2: Endometrial Cancer and Cervical Cancer — Susana Banerjee, MBBS, MA, PhD

CME information and select publications

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Gynecologic Cancers | Faculty Presentation 1: Ovarian Cancer — Ursula Matulonis, MD

CME information and select publications

Featuring an interview with Ms Kathleen D Burns, including the following topics:

• Case: A man in his early 70s with metastatic hormone-sensitive prostate cancer who received an androgen receptor inhibitor in combination with androgen deprivation therapy (0:00)
• Case: A man in his early 70s with metastatic castration-resistant prostate cancer (mCRPC) who received olaparib in combination with abiraterone (23:20)
• Case: A man in his mid 70s with mCRPC who received lutetium Lu 177 vipivotide tetraxetan (33:44)

NCPD information and select publications

Featuring an interview with Dr Hope S Rugo, including the following topics:

• Pharmacologic features of antibody-drug conjugates (ADCs) and implications for their efficacy and toxicity in HR-positive breast cancer (0:00)
• Clinical and biological factors influencing the sequencing of approved ADCs for HR-positive and triple-negative metastatic breast cancer (4:03)
• Management of common toxicities with approved ADCs (10:48)
• Sacituzumab govitecan as first-line therapy for metastatic triple-negative breast cancer (18:17)
• Trastuzumab deruxtecan in combination with pertuzumab as first-line therapy for HER2-positive metastatic breast cancer (21:09)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Hope S Rugo, including the following topics:

• Current treatment landscape for and outcomes in HR-positive, HER2-negative metastatic breast cancer (mBC) (0:00)
• Trastuzumab deruxtecan for HER2-low and HER2-ultralow mBC (7:49)
• Sacituzumab govitecan for HR-positive, HER2-negative mBC (20:44)
• Datopotamab deruxtecan for HR-positive, HER2-negative mBC (27:29)
• Novel antibody-drug conjugates under investigation for HR-positive mBC (33:19)

CME information and select publications

Featuring perspectives from Dr Rashmi Chugh and Dr Mrinal Gounder, including the following topics:

• Introduction: Current Role of General Medical Oncologists in the Treatment of Soft Tissue Sarcomas (STS) (0:00)
• Incorporation of Novel Agents and Strategies into the Management of STS — Faculty Presentation (6:38)
• Incorporation of Novel Agents and Strategies into the Management of STS — Survey Questions (20:34)
• Evolving Treatment Paradigm for Locally Aggressive STS — Faculty Presentation (31:09)
• Evolving Treatment Paradigm for Locally Aggressive STS — Survey Questions (46:44)

CME information and select publications

Featuring perspectives from Prof Laurence Albiges and Dr Tian Zhang, including the following topics:

• Introduction: Adjuvant Immunotherapy for Localized Renal Cell Carcinoma (RCC) (0:00)
• Metastatic Clear Cell RCC — Faculty Presentation (9:22)
• Metastatic Clear Cell RCC — Survey Questions (20:24)
• Non-Clear Cell RCC — Faculty Presentation (36:02)
• Non-Clear Cell RCC — Survey Questions (45:46)
• ASCO 2025 (50:12)

CME information and select publications

Featuring perspectives from Dr Catherine C Coombs and Dr William G Wierda, including the following topics:

• Introduction (0:00)
• Selection and Sequencing of Therapy for Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) — Dr Wierda (19:25)
• First-Line Therapy for CLL — Dr Coombs (44:18)
• Novel Agents and Strategies for R/R CLL — Dr Wierda (57:27)

CME information and select publications